Hyun Jin Song1,2, Kiyon Rhew3, Yoon Jae Lee4, In-Hyuk Ha4. 1. School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. hyunjin.song@cop.ufl.edu. 2. Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, HPNP Building Room 2320, 1225 Center Drive, Gainesville, FL, 32610, USA. hyunjin.song@cop.ufl.edu. 3. College of Pharmacy, Dongduk Women's University, Seoul, South Korea. 4. Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, South Korea.
Abstract
BACKGROUND: Patients with cancer often receive acid-suppressive agents (ASAs) to treat common gastroesophageal reflux and peptic ulcer diseases. Our systematic review addresses the association between ASAs and survival outcomes in these patients. METHODS: We searched MEDLINE, EMBASE, and Cochrane until December 2019, including randomized controlled trials (RCTs), quasi-RCTs, and observational studies concerning ASAs that reported progression-free survival (PFS) and/or overall survival (OS). We estimated hazard ratios (HRs) with 95% confidence intervals (CIs) using the random-effects model, and assessed heterogeneity with I2 statistic. RESULTS: We included 45,626 patients from 7 RCTs and 18 observational studies, including esophageal/gastric, colorectal, pancreatic, lung, breast, prostate, kidney, and other cancers. Five studies showed that ASAs in lung cancer patients received tyrosine kinase inhibitors (TKIs) had significantly worse PFS (HR 1.64, 95% CI 1.14 - 2.37, I2 = 57%) and OS (HR 1.13, 95% CI 1.05 - 1.21, I2 = 0%) than nonusers. Each of five studies found no significant association between ASAs and OS in esophageal/gastric (HR 0.91, 95% CI 0.77 - 1.09, I2 = 32%) or colorectal cancer patients (HR 1.33, 95% CI 0.96- 1.85, I2 = 0%). ASAs were not significantly associated with an OS in patients with kidney cancer (HR 1.04, 95% CI 0.96 - 1.13, I2 = 28%). CONCLUSIONS: Meta-analysis showed that ASAs significantly associated with an increased mortality risk in lung cancer patients treated TKIs, but not in patients with esophageal/gastric, colorectal, or kidney cancer. Until further studies confirm these results, caution should be used when administering ASAs and TKIs to patients with lung cancer.
BACKGROUND:Patients with cancer often receive acid-suppressive agents (ASAs) to treat common gastroesophageal reflux and peptic ulcer diseases. Our systematic review addresses the association between ASAs and survival outcomes in these patients. METHODS: We searched MEDLINE, EMBASE, and Cochrane until December 2019, including randomized controlled trials (RCTs), quasi-RCTs, and observational studies concerning ASAs that reported progression-free survival (PFS) and/or overall survival (OS). We estimated hazard ratios (HRs) with 95% confidence intervals (CIs) using the random-effects model, and assessed heterogeneity with I2 statistic. RESULTS: We included 45,626 patients from 7 RCTs and 18 observational studies, including esophageal/gastric, colorectal, pancreatic, lung, breast, prostate, kidney, and other cancers. Five studies showed that ASAs in lung cancerpatients received tyrosine kinase inhibitors (TKIs) had significantly worse PFS (HR 1.64, 95% CI 1.14 - 2.37, I2 = 57%) and OS (HR 1.13, 95% CI 1.05 - 1.21, I2 = 0%) than nonusers. Each of five studies found no significant association between ASAs and OS in esophageal/gastric (HR 0.91, 95% CI 0.77 - 1.09, I2 = 32%) or colorectal cancerpatients (HR 1.33, 95% CI 0.96- 1.85, I2 = 0%). ASAs were not significantly associated with an OS in patients with kidney cancer (HR 1.04, 95% CI 0.96 - 1.13, I2 = 28%). CONCLUSIONS: Meta-analysis showed that ASAs significantly associated with an increased mortality risk in lung cancerpatients treated TKIs, but not in patients with esophageal/gastric, colorectal, or kidney cancer. Until further studies confirm these results, caution should be used when administering ASAs and TKIs to patients with lung cancer.
Authors: Md Mohaimenul Islam; Tahmina N Poly; Bruno A Walther; Navneet K Dubey; Dina N Anggraini Ningrum; Syed-Abdul Shabbir; Yu-Chuan Jack Li Journal: Eur J Gastroenterol Hepatol Date: 2018-12 Impact factor: 2.566
Authors: Glen T Schumock; Edward C Li; Katie J Suda; Michelle D Wiest; JoAnn Stubbings; Linda M Matusiak; Robert J Hunkler; Lee C Vermeulen Journal: Am J Health Syst Pharm Date: 2016-05-11 Impact factor: 2.637
Authors: Manvi Sharma; Holly M Holmes; Hemalkumar B Mehta; Hua Chen; Rajender R Aparasu; Ya-Chen T Shih; Sharon H Giordano; Michael L Johnson Journal: Cancer Date: 2019-01-03 Impact factor: 6.860
Authors: P Laoveeravat; S Thavaraputta; W Vutthikraivit; S Suchartlikitwong; T Mingbunjerdsuk; A Motes; K Nugent; A Rakvit; E Islam; S Islam Journal: QJM Date: 2020-02-01
Authors: Vincent H Ha; Margaret Ngo; Michael P Chu; Sunita Ghosh; Michael B Sawyer; Carole R Chambers Journal: J Oncol Pharm Pract Date: 2014-03-24 Impact factor: 1.809
Authors: Ezequiel Monferrer; Isaac Vieco-Martí; Amparo López-Carrasco; Fernando Fariñas; Sergio Abanades; Luis de la Cruz-Merino; Rosa Noguera; Tomás Álvaro Naranjo Journal: Metabolites Date: 2021-04-23